In CLL patients with very high white blood cell counts (>200k), initiating therapy with a BTK inhibitor alone risks redistribution lymphocytosis, which can lead to symptomatic hyperviscosity. An approach that includes early debulking with an anti-CD20 antibody like obinutuzumab is preferred to mitigate this dangerous complication.

With highly effective CLL therapies, primary causes of mortality are now infections and secondary cancers from immunodeficiency. Research is now focusing on immune reconstitution after treatment, marking a pivotal shift towards managing long-term survivorship challenges beyond just controlling the leukemia itself.

While these drugs can cause neutropenia, it rarely leads to infections. Patients often feel clinically well despite low neutrophil counts. This 'paper problem' can usually be managed with G-CSF without needing to dose-reduce the primary CLL therapy.

Improved T-cell function in CLL patients on BTK inhibitors is probably a result of the substantial reduction in disease burden, allowing the immune system to normalize. This effect is seen across different BTK inhibitors, challenging the older hypothesis that it was a specific off-target effect (ITK inhibition) of ibrutinib.

T-cell engagers (TCEs) are likely to be safer in autoimmune conditions than in cancer. Autoimmune patients have a relatively normal B-cell count, unlike the massive proliferation in hematologic cancers. This lower target cell burden naturally limits the scale of T-cell activation and inflammatory toxicity.

If a patient's CLL therapy is stopped for another major health issue, such as a second cancer, clinicians should often observe them post-recovery rather than immediately restarting treatment. This approach is recommended even with detectable Minimal Residual Disease (MRD) to prioritize the patient's immune system recovery and overall health.

In complex, real-world CLL cases with elderly patients and comorbidities, the 'art of medicine' prevails. Opting for a less intensive, guideline-deviant therapy like single-agent obinutuzumab can be a reasonable choice to control symptoms and improve quality of life, prioritizing safety over maximal PFS.

Data across multiple studies consistently shows that creating a triplet therapy by adding an antibody to an oral doublet significantly increases the risk of high-grade infections and cytopenias. This makes the two-drug oral combination a safer approach for managing Chronic Lymphocytic Leukemia (CLL).

Despite updated ASH guidelines suggesting its use, some experts avoid upfront rituximab because it's not disease-modifying and may worsen the long-term autoimmune response. They prefer to reserve it for later-line or salvage settings rather than initial combination therapy.